| 0.775 0.007 (0.85%) | 09-07 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.72  |
1-year : | 0.82 |
| Resists | First : | 0.61 |
Second : | 0.7 |
| Pivot price | 0.56 |
|||
| Supports | First : | 0.46 | Second : | 0.39 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.57 |
| MA(100) : | 1.2 |
MA(250) : | 6.6 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 11.3 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 21.69 | Low : | 0.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ADMP ] has closed above bottom band by 26.8%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.55 | 0.55 - 0.55 |
| Low: | 0.47 - 0.48 | 0.48 - 0.48 |
| Close: | 0.52 - 0.52 | 0.52 - 0.52 |
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Thu, 07 Sep 2023
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus - Yahoo Finance
Fri, 04 Aug 2023
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering - Yahoo Finance
Thu, 25 May 2023
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals - GlobeNewswire
Fri, 19 May 2023
Adamis Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance
Thu, 16 Mar 2023
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, 27 Feb 2023
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 16.5 (%) |
| Shares Short | 99 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -10.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.24 |
| Profit Margin | 0 % |
| Operating Margin | -373.7 % |
| Return on Assets (ttm) | -104.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -82.6 % |
| Gross Profit (p.s.) | -0.16 |
| Sales Per Share | 0.53 |
| EBITDA (p.s.) | -1.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | -0.13 |
| Price to Sales | 0.96 |
| Price to Cash Flow | -0.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|